Literature DB >> 27207679

The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.

Jelena Dackovic1, Tatjana Pekmezovic2, Sarlota Mesaros3, Irena Dujmovic3, Nebojsa Stojsavljevic3, Vanja Martinovic3, Jelena Drulovic3.   

Abstract

Cognitive impairment is prevalent in multiple sclerosis (MS) occurring in 43-72 % of patients with all MS phenotypes. The aim of our study was to assess cognitive performance in different MS subtypes in Serbian population. Rao's Brief Repeatable Battery of neuropsychological tests (BRB-N) was administered to 168 MS patients [37 patients with clinically isolated syndrome (CIS) suggestive of MS, 65 with relapsing-remitting MS (RRMS), 31 with secondary progressive MS (SPMS) and 35 patients with primary progressive MS (PPMS)]. The percentage of cognitively impaired patients in our total MS cohort was 58.9 %. Prevalence of cognitive dysfunction was 40.5 % in CIS group, 36.9 % in RRMS, 96.8 % in SPMS, and 85.7 % in PPMS group. Patients in CIS and RRMS groups performed consistently better all tests of the Rao's battery than patients in SPMS and PPMS cohort. CIS and RRMS groups performed consistently better in all tests of the Rao's battery than SPMS and PPMS cohort. Additionally, difference in the performance of any of the BRB-N tests was not found between CIS and RRMS. However, there was a significant difference between SPMS and PPMS patients in the performance on five tests of Rao's battery. Statistical significance (p < 0.05) in favor of PPMS patients was demonstrated for the following tasks: SRT_lts, SRT_cltr, SDMT, SRT_D, SPART_D. Our study demonstrates that cognitive impairment is frequent in all MS phenotypes. Furthermore, we have found that cognitive deficit is most severe and most frequent in SPMS patients, followed by PPMS subjects and then CIS and RRMS patients.

Entities:  

Keywords:  Brief Repeatable Battery of neuropsychological tests; Cognitive impairment; Depression; Disability; Multiple sclerosis

Mesh:

Year:  2016        PMID: 27207679     DOI: 10.1007/s10072-016-2610-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  38 in total

Review 1.  Cognition in multiple sclerosis.

Authors:  Dawn W Langdon
Journal:  Curr Opin Neurol       Date:  2011-06       Impact factor: 5.710

2.  Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test.

Authors:  J Sepulcre; S Vanotti; R Hernández; G Sandoval; F Cáceres; O Garcea; P Villoslada
Journal:  Mult Scler       Date:  2006-04       Impact factor: 6.312

3.  Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study.

Authors:  Maria P Amato; Emilio Portaccio; Benedetta Goretti; Valentina Zipoli; Alfonso Iudice; Dario Della Pina; Gianmichele Malentacchi; Simonetta Sabatini; Pasquale Annunziata; Mario Falcini; Monica Mazzoni; Marzia Mortilla; Claudio Fonda; Nicola De Stefano
Journal:  Mult Scler       Date:  2010-08-20       Impact factor: 6.312

4.  Paced auditory serial-addition task: a measure of recovery from concussion.

Authors:  D M Gronwall
Journal:  Percept Mot Skills       Date:  1977-04

Review 5.  Cognitive impairment and decline in different MS subtypes.

Authors:  Stephan C J Huijbregts; Nynke F Kalkers; Leo M J de Sonneville; Vincent de Groot; Chris H Polman
Journal:  J Neurol Sci       Date:  2006-04-27       Impact factor: 3.181

6.  Evaluating storage, retention, and retrieval in disordered memory and learning.

Authors:  H Buschke; P A Fuld
Journal:  Neurology       Date:  1974-11       Impact factor: 9.910

7.  Clinical and psychometrical study of a patient with memory disturbances.

Authors:  J Barbizet; E Cany
Journal:  Int J Neurol       Date:  1968

8.  The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.

Authors:  D Obradovic; M Petrovic; I Antanasijevic; J Marinkovic; T Stojanovic; S Obradovic
Journal:  Neurol Sci       Date:  2012-05-03       Impact factor: 3.307

9.  Cognitive impairment in different MS subtypes and clinically isolated syndromes.

Authors:  Constantin Potagas; Erasmia Giogkaraki; Georgios Koutsis; Dimitrios Mandellos; Erifylli Tsirempolou; Constantin Sfagos; Demetris Vassilopoulos
Journal:  J Neurol Sci       Date:  2007-11-13       Impact factor: 3.181

10.  Cognitive function in patients with multiple sclerosis.

Authors:  J M Peyser; K R Edwards; C M Poser; S B Filskov
Journal:  Arch Neurol       Date:  1980-09
View more
  5 in total

1.  Advances in clinical neurology through the journal "Neurological Sciences" (2015-2016).

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2017-01       Impact factor: 3.307

2.  Integrated Cognitive Rehabilitation Home-Based Protocol to Improve Cognitive Functions in Multiple Sclerosis Patients: A Randomized Controlled Study.

Authors:  Minoo Sharbafshaaer; Francesca Trojsi; Simona Bonavita; Amirreza Azimi
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

3.  The Expanded Disability Status Scale Score and Demographic Indexes Are Correlated with the Severity of Cognitive Impairment in Multiple Sclerosis Patients.

Authors:  Saeed Sadigh-Eteghad; Negin Abbasi Garravnd; Mahsa Feizollahi; Mahnaz Talebi
Journal:  J Clin Neurol       Date:  2021-01       Impact factor: 3.077

Review 4.  Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype.

Authors:  Bruno Brochet; Pierre Clavelou; Gilles Defer; Jérôme De Seze; Céline Louapre; Eloi Magnin; Aurélie Ruet; Catherine Thomas-Anterion; Patrick Vermersch
Journal:  Brain Sci       Date:  2022-01-29

5.  Brain activity pattern changes after adaptive working memory training in multiple sclerosis.

Authors:  Laura Bonzano; Ludovico Pedullà; Matteo Pardini; Andrea Tacchino; Paola Zaratin; Mario Alberto Battaglia; Giampaolo Brichetto; Marco Bove
Journal:  Brain Imaging Behav       Date:  2020-02       Impact factor: 3.978

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.